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ABSTRACT:
Predictive assays are needed to help optimise treatment in muscle-invasive 
bladder cancer, where patients can be treated by either cystectomy or radical 
radiotherapy. Our finding that low tumour MRE11 expression is predictive of poor 
response to radiotherapy but not cystectomy was recently independently validated. 
Here we investigated further the mechanism underlying low MRE11 expression seen 
in poorly-responding patients. MRE11 RNA and protein levels were measured in 
88 bladder tumour patient samples, by real-time PCR and immunohistochemistry 
respectively, and a panel of eight bladder cancer cell lines was screened for MRE11, 
RAD50 and NBS1 mRNA and protein expression. There was no correlation between 
bladder tumour MRE11 protein and RNA scores (Spearman’s rho 0.064, p=0.65), 
suggesting MRE11 is controlled post-transcriptionally, a pattern confirmed in eight 
bladder cancer cell lines. In contrast, NBS1 and RAD50 mRNA and protein levels 
were correlated (p=0.01 and p=0.03, respectively), suggesting primary regulation 
at the level of transcription. MRE11 protein levels were correlated with NBS1 and 
RAD50 mRNA and protein levels, implicating MRN complex formation as an important 
determinant of MRE11 expression, driven by RAD50 and NBS1 expression. Our findings 
of the post-transcriptional nature of the control of MRE11 imply that any predictive 
assays used in patients need to be performed at the protein level rather than the 
mRNA level.
INTRODUCTION
Muscle invasive bladder cancer can be treated by 
surgical removal of the bladder (cystectomy) or radical 
radiotherapy, with similar cure rates [1]. However, it 
is not currently possible to choose the better option 
for an individual patient, based on known clinico-
pathological parameters. There is therefore an urgent 
need to develop predictive biomarkers in this disease. 
In two cohorts of radiotherapy patients, we found that 
patients whose tumours expressed low levels of the 
DNA damage signalling protein, MRE11, as measured 
by immunohistochemistry (IHC), had a significantly 
worse survival rate following radiotherapy than those 
expressing high levels of MRE11 (43% versus 70% 3-year 
cause-specific survival) [2]. Low MRE11 expression 
was predictive of poor response to radiotherapy, rather 
than being a prognostic marker in bladder cancer, as 
expression was not correlated with outcome in our surgical 
cohort. More recently, Laurberg et al [3] confirmed our 
MRE11 IHC findings in a Danish surgical and German 
chemoradiotherapy cohort. We observed lower MRE11 
expression in tumour cells than normal urothelium [2], as 
seen previously in breast tumours [4, 5]; low MRE11 was 
associated with poorer radiotherapy outcomes in breast 
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cancer [5].
MRE11 is a component of the MRN complex with 
RAD50 and NBS1, and stability of the three MRN proteins 
is linked, with MRE11 mutations which destabilise the 
MRN complex being associated with reduced RAD50 and 
NBS1 protein levels [6]. Re-expression of MRE11 in such 
mutant cells results in increased levels of MRE11, RAD50 
and NBS1 proteins [6, 7]. The MRN complex contributes 
to the DNA damage response, detecting DNA breaks 
and signalling to checkpoint kinases [8]. The crystal 
structure of the human MRE11 core has recently been 
determined [9]. Through its exonuclease activity, MRE11, 
along with CtIP, resects DNA ends during homologous 
recombination [10] and promotes microhomology-
mediated end-joining over conventional non-homologous 
end-joining [11]. MRE11 is also required for telomeric 
maintenance [12]. Cells defective in MRE11 expression 
are unusually radiosensitive [6], and treatment with the 
MRE11 inhibitor Mirin results in inhibition of radiation-
induced phosphorylation of ATM [13, 14]. Therefore our 
validated IHC result was intriguing, as it was anticipated 
that reduced expression of proteins involved in DNA 
repair such as MRE11 would increase patient survival 
after radiotherapy, through greater tumour radiosensitivity 
from reduced repair of DNA double-strand breaks. 
The aims of the present study were to further 
our understanding of the mechanisms underlying the 
low tumour MRE11 protein expression seen in poorly 
responding bladder cancer patients, as potentially this 
could be exploited clinically, and to determine the level 
of control, relative to transcription. We wished to test the 
hypotheses that underlying control mechanisms determine 
MRE11 protein expression levels, and that expression 
levels of NBS1 and RAD50 might also influence MRE11 
expression.
RESULTS 
MRE11 protein expression is controlled at the 
post-transcriptional level and correlates with 
expression of RAD50 and NBS1
To determine the range of MRE11 protein 
expression levels in radiotherapy patients’ tumour 
samples and to determine whether control of expression 
occurs pre- or post-transcriptionally, FFPE patient tumour 
sections were stained by IHC for MRE11 and 0.6 mm 
cores taken from a homogeneous tumour area for RNA 
extraction. RNA of sufficient quantity and quality was 
extracted from 83 of 88 tumours. Fourteen tumours were 
excluded as the combined Ct value for both endogenous 
controls was greater than two standard deviations from 
Figure 1: Bladder tumour MRE11 RNA and protein expression levels. a) QPCR of RNA from FFPE bladder tumours (n=53), 
using SDHA and ATPB as endogenous controls. Data points represent values relative to the lowest value above zero. Error bars represent 
the standard error of the mean (SEM) from technical duplicates. b) Tumour MRE11 QPCR and IHC scores expressed relative to the highest 
value for each.
a
b
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the mean; a further 16 tumours were excluded due to 
inconsistencies between technical replicates. Fifty-three 
tumours yielded high quality data that were normalised 
against endogenous controls and set relative to the highest 
value (Figure 1). MRE11 RNA expression was below 
detectable levels in eight tumours, but PCR failure was 
ruled out as other experiments on the same plate were 
successful and the result was repeated on at least one 
other occasion. This result was therefore taken to represent 
extremely low MRE11 RNA expression. IHC scores were 
also plotted relative to the highest value and compared to 
QPCR results. Spearman Rank Correlation revealed no 
correlation between protein and RNA scores (Spearman’s 
rho (ρ) 0.064, p=0.65), suggesting that differences in 
MRE11 protein expression occur as a result of post-
transcriptional events.
The same Taqman assay was used to detect MRE11 
RNA expression in a panel of bladder cancer cell lines and 
a similar discordance was seen between RNA expression 
and protein expression, by western blotting (Figure 2, 
p=0.42, and Supplementary Figure 1). However, RNA and 
protein expression were correlated for both NBS1 (p=0.01) 
and RAD50 (p=0.03), using SYBR green. While there was 
no correlation between MRN complex members’ mRNA 
expression levels, western blot quantification revealed 
correlations between MRE11, RAD50 and NBS1 protein 
expression (all p=0.002 or less), and MRE11 protein levels 
also correlated with both RAD50 and NBS1 mRNA levels 
(Figure 2b).
microRNA-153 expression is associated with 
reduced MRE11 protein expression
In our clinical samples, MRE11 appeared to be 
controlled at the post-transcriptional level. Therefore we 
decided to study various factors which could be involved, 
namely RNA stability, protein translation initiation and 
protein stability. Binding of microRNAs to the 3’UTRs 
of mRNAs, a major post-transcriptional gene regulatory 
mechanism, inhibits translation of messenger RNA, 
by targeting it for degradation or inhibiting translation 
initiation. 
The online database Targetscan identified miR-
9 and miR-153 as having a high probability of binding 
to MRE11’s 3’UTR (Fig 3a), and these miRNAs have 
higher expression in urothelial tumours than normal 
tissues (J Catto, personal communication, 30 Oct 2013). 
Therefore luciferase assays were performed in which 
either pre-miR-9 or pre-miR-153 was co-transfected with 
an MRE11 3’UTR-luciferase construct into 5637 bladder 
cancer cells (Figure 3b and Supplementary figure 2), 
chosen for transfection efficiency of both plasmid DNA 
constructs and small RNAs. miR-9 had a small, borderline 
significant effect on luciferase activity (p=0.06), whereas 
transfection of miR-153 markedly reduced luciferase 
activity (p=0.002). This functional assay suggested that 
miR-153 can bind the MRE11 3’UTR and inhibit gene 
expression, whereas miR-9 has only a relatively weak 
effect. 
Expression of miR-9 and miR-153 was determined 
Figure 2: Expression of MRE11, RAD50 and NBS1 RNA and protein in eight bladder cancer cell lines. a) comparison 
of QPCR and western blotting data for RAD50 (ρ=0.762, p=0.03), NBS1 (ρ=0.833, p=0.01) and MRE11 (Spearman’s rho 0.333, p=0.42). 
Error bars: SEM of three experiments. b) Spearman correlation coefficients (top) with p values (bottom) for each comparison.
a
b
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by QPCR in tumours using total RNA extracted from 
FFPE tissues from additional tumour cores, mentioned 
previously. miRNAs, being much smaller than mRNA 
can be reliably measured in FFPE material [15]. Sixty-
two tumours yielded RNA of sufficient quality and 
quantity for analysis. Six tumours were excluded as 
combined levels of endogenous controls RNU44 and 
RNU48 were over two standard deviations from the mean, 
leaving 56 tumours with high quality data available. Two 
tumours were excluded from the miR-153 study due to 
inconsistencies in technical replicates or QPCR failure. 
In general, expression of both microRNAs was low, with 
higher expression in relatively few tumours (Figure 3 
c-d). There was no correlation between miR-9 expression 
and MRE11 IHC score (p=0.14), but miR-153 expression 
was inversely correlated with IHC expression (ρ-0.403, 
p=0.003), consistent with our in vitro data.
Translation initiation does not affect MRE11 
expression
Although we observed a relationship between miR-
153 and protein levels for MRE11, no correlation was 
observed with mRNA expression (data not shown). We 
hypothesized that miR-153 could influence protein levels 
by inhibiting translation initiation of MRE11 in bladder 
Figure 4: Polysome assay performed on T24 and 253J 
cells. a) example polysome plot of overall translation, with sum 
of total RNA for each cell line derived from polysome plot; b)(i) 
Example of distribution of RNA in fraction pools corresponding 
to 0-1 (light grey), 2-4 (medium grey), 5-7 (dark grey) and >7 
(black) ribosomes. (ii) average ribosome number per mRNA 
of total RNA, c(i) Example of MRE11 transcript distribution 
across fraction pools as determined by QPCR (legend as for 
b(i)), (ii) mean ribosome number per MRE11 mRNA, (iii) 
rate of translation of MRE11 adjusted for global differences in 
translation.
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Figure 3: Effects of microRNA-9 and microRNA-153 
on MRE11 protein expression in bladder cancer. a) 
binding sites of miRNAs to MRE11 3’UTR; b) transfection of 
5637 cells with a construct containing the MRE11 3’UTR cloned 
downstream of firefly luciferase, pre-miR-9, pre-miR-153 
or negative control, and renilla luciferase internal control; c) 
correlation between microRNA-9 (n=56), and d) microRNA-153 
expression (n=54) with bladder tumour MRE11 IHC protein 
expression. Error bars: SEM of technical duplicates.
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tumours. We therefore assessed whether or not protein 
expression of MRE11 was influenced at the level of 
translation initiation using the polysome assay. The T24 
cell line has a lower MRE11 protein:RNA ratio (1:1.7) 
than the 253J cell line (1:0.5) so we hypothesised that 
translation initiation in T24 cells would be lower than in 
253J cells. QPCR was carried out on RNA extracted from 
fractions separated on a sucrose gradient corresponding to 
those mRNAs attached to 0-1, 2-4, 5-7 or 7+ ribosomes. 
The overall levels of protein synthesis (percentage 
of ribosomes involved in translation) was similar in 
both lines (Figure 4a). The distribution of mRNA within 
the polysome gradient was also similar (Figure 4bi). 
The average ribosome number per mRNA transcript, 
determined from these distributions, was slightly lower 
for 253J cells although this did not reach statistical 
significance (Figure 4bii). In contrast to our hypothesis, 
QPCR demonstrated no significant differences in MRE11 
translation between the two cell lines, even once adjusted 
to compensate for differences in global translation by 
normalisation against average ribosome number per 
mRNA transcript (Figure 4c, p=0.15). These data suggest 
that the discrepancy between MRE11 mRNA and protein 
levels cannot be explained in these two cell lines by 
differences in translation initiation, nor was there a 
difference in miR-153 levels (Supplementary Figure 4).
Bladder cancer cell lines have generally stable 
MRE11, RAD50 and NBS1 mRNA and protein 
levels
RNA stability was measured by treatment with 
1 ug/ml Actinomycin D, an inhibitor of transcription, 
followed by QPCR using SYBR Green. The efficacy 
of Actinomycin D is reflected in the rapid decrease in 
c-MYC RNA in all cell lines (Figure 5a). MRE11 and 
NBS1 were relatively stably expressed in all three lines 
tested (Supplementary Figure 3); RAD50 was also stable 
in T24 cells but RAD50 mRNA levels fell by 37.2% 
(p=0.0052) and 34.1% (p=0.019) in 253J and RT112 cells, 
respectively, by 6 hours, with half lives calculated as 229 
hours and 2.45 hours. All half-lives were statistically 
significantly greater than those of c-Myc in individual 
cell lines (Figure 5b and Supplementary Table 3), and 
represent a general high level of stability for all three 
MRN transcripts.
Protein stability was determined by treating 
cells with 100 µg/ml cycloheximide for up to 30 hours 
(Figure 6). Cell death prevented study over a longer time 
period. RAD51 levels fell relatively rapidly, confirming 
cycloheximide’s ability to inhibit further translation. All 
three proteins were significantly more stable than RAD51, 
with half-lives of at least 25 hours. All half-lives were 
statistically significantly greater than those of RAD51 in 
individual cell lines (Supplementary Table 3). There were 
no statistically significant differences in degradation of 
MRE11, RAD50 or NBS1 between cell lines.
DISCUSSION
The aim of this study was to further investigate 
our observation that patients with low tumour MRE11 
expression do worse following radical radiotherapy than 
high MRE11 expressors [2]. At the start of this study it 
was not known whether control of MRE11 expression 
was at the pre-transcriptional (i.e. mutation of the MRE11 
gene or epigenetic silencing of MRE11), transcriptional or 
post-transcriptional level. Post-transcriptional processes 
involved in control of gene expression include mRNA 
degradation, translation and protein degradation [16]. 
Also, as the three proteins act in a complex, MRE11 
protein expression may be influenced by NBS1 or RAD50 
expression.
To compare mRNA and protein expression, 
we selected a small tumour area for IHC scoring and 
removal of tissue cores for mRNA extraction and QPCR 
RNA quantification. We found that MRE11 protein and 
RNA expression were discordant, implying that MRE11 
expression is subject to post-transcriptional control. Post-
transcriptional gene regulation is widespread in the cell 
and accounts for up to 60% of protein abundance [17, 
Figure 5: a) c-MYC RNA stability and b) RAD50 RNA stability in T24, 253J and RT112 cells. Relative data expressed 
relative to time zero = 1.0 for each transcript. Error bars: SEM of three independent experiments.
a b 
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18]. The selection of a small tumour area was necessary, 
as we previously found that tumour chips from TURBT 
specimens frequently show heterogeneous MRE11 
staining. We found no association between MRE11 
protein expression in our single TURBT chip per patient 
and survival on Kaplan-Meier analysis (data not shown), 
unlike our previous study, but this reflects our inability 
to measure tumour heterogeneity in our single chip 
[19]. This highlights the need to assess all tumour areas 
immunohistochemically for predictive purposes.
Our clinical findings of discordant MRE11 mRNA/
protein expression were backed up by the cell line data, 
which additionally showed concordant RAD50 protein/
mRNA and NBS1 protein/mRNA levels, suggesting 
MRE11 expression is regulated by a post-transcriptional 
mechanism but not RAD50 or NBS1. Since this study 
began, Garner and Eastman [20] studied MRN expression 
in the NCI60 cell line panel, which does not include 
bladder cancer lines, and found strong correlations for 
protein expression but not mRNA expression. However, 
MRE11 RNA and protein expression were more highly 
correlated than for NBS1 and RAD50, suggesting control 
of MRE11 at the transcription level. In contrast, our 
findings suggest that in bladder cancer transcriptional 
control dominates for RAD50 and NBS1, but MRE11 
expression is regulated at the post-transcriptional level. 
Garner and Eastman concluded that it was the MRN 
complex formation that determined protein stability. 
Despite the different underlying mechanisms, our data 
would concur with this finding. In our study RAD50 and 
Figure 6: MRE11, RAD50 and NBS1 protein stability in T24, RT112 and 253J cells measured using cycloheximide 
assay. a) western blots in (i) T24, (ii) RT112, (iii) 253J cells, b) quantification curves for (i) RAD51, (ii) RAD50, (iii) NBS1, (iv) MRE11. 
Relative data is expressed relative to 1.0 at time zero for each transcript. Error bars: SEM of three independent experiments.
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NBS1 mRNA levels correlated with expression of all three 
proteins (borderline for NBS1 mRNA and RAD50 protein, 
p=0.058), implying that these two genes are driving the 
formation of the protein complex, with the MRE11 protein 
expression then determined by its binding to the complex, 
with degradation of protein molecules that are not required 
for complex formation. 
MicroRNAs are small, 22-27 nucleotide length, non-
coding RNAs sequences which bind to complementary 
binding sites in the 3’UTR of mRNAs, resulting in 
mRNA degradation if there is extensive base-pairing 
complementarity, or inhibition of mRNA translation 
if complementarity is limited. Either results in post-
transcriptional gene silencing [21]. Targetscan identified 
miR-9 and miR-153 as potential binding partners for the 
MRE11 3’UTR. In addition, miR-9 and mir-153 have 
been detected in 94% and 54% of urothelial carcinomas, 
respectively (J Catto, personal communication, 30 Oct 
2013) with 2.7 and 2.8-fold increases in expression 
relative to normal urothelial tissue, and we found miR-
9 expression in 100% and miR-153 in 76% of tumours. 
However, expression was generally low, which may limit 
their functional impact to a subset of tumours. 
Our luciferase assays demonstrated that pre-
miR-153 transfection resulted in reduced expression of the 
MRE11 3’UTR, which was compatible with our clinical 
data, where low miR-153 expression was associated 
with high MRE11 protein expression in clinical samples. 
It is biologically plausible that miR-153 binding to the 
MRE11 3’UTR could inhibit MRE11 protein expression, 
through mRNA degradation or the inhibition of translation 
initiation. 
In mouse fibroblasts, Schwanhausser et al 
found translation rates to be the most important factor 
determining protein abundance (approx 55%), followed 
by transcription (approx 34%), with mRNA and protein 
stability less important [16]. Our polysome assay results 
suggest that the rate of translation of MRE11 may not be 
an important determinant of MRE11 protein expression 
in bladder cancer, although we only studied two cell 
lines. Our data support findings that mRNA and protein 
stability are the least important factors determining protein 
abundance. The actinomycin D assay revealed relatively 
stable mRNA levels for all three genes across three cell 
lines, with half lives of at least 2.45 hours compared to a 
mean half live of 33 minutes for RAD51, and data from 
our cycloheximide experiments showed that all three 
proteins were also relatively stable with a minimum half 
life of 23.5 hours compared to a mean of 12.1 hours for 
c-Myc (Supplementary Table 3). 
Our findings are biologically plausible in terms of 
the MRN complex, as all three proteins are located in 
the nucleus and involved in the DNA damage response. 
For this, the fully-formed proteins are required to move 
rapidly to sites of damage to form foci, involved in 
damage recognition and repair, and there is not sufficient 
time for transcription and/or translation to form new 
protein molecules [22], so proteins with long half-lives 
are needed. Interestingly, RT112 cells had a lower MRE11 
band, not present in the other two cell lines, which 
declined more rapidly than the full-length protein, and this 
needs to be investigated further.
Whilst we have studied a number of post-
transcriptional mechanisms of MRE11 expression, we 
have not ruled out the possibility that transcriptional 
or pre-transcriptional mechanisms might be involved 
rarely in individual tumours. Both epigenetic and genetic 
changes, such as amplification of chromosome 6p22.3, are 
known to contribute to the development of bladder cancer 
[23]. Promoter hypermethylation of MRE11 has not been 
detected in previous bladder cancer studies, nor have gene 
mutations such as the A poly(T) MRE11 mutation at the 
intron 4 splice site, seen in upper urinary tract tumours 
with microsatellite instability [24]. This -1 to -2 frameshift 
mutation in a run of 11 thymidine residues results in 
deletion of exons 5 to 7 of MRE11, and reduced expression 
of a protein lacking exonuclease activity [25-27]. All our 
cell lines were screened and none carried this mutation. 
In the presence of such a mutation, MRE11 expression 
could drive the expression of the MRN complex, as the 
least abundant protein. Alternative MRE11 transcripts 
that do not result in a fully functional protein, but which 
act in a dominant-negative manner, could be detected by 
QPCR. However, all our MRE11 primers targeted the two 
common transcripts 1 and 2, and our antibody, binding 
amino acids 182 to 582, detects both protein isoforms.
In conclusion, we have found that, in muscle-
invasive bladder tumour samples and a panel of bladder 
cancer cell lines, MRE11 expression is regulated at the 
post-transcriptional level, while RAD50 and NBS1 
undergo transcriptional control. We have investigated a 
number of post-transcriptional mechanisms, and found 
that miRNA-153 expression was inversely correlated 
with MRE11 expression, although miR-153 was only 
highly expressed in a few tumours, limiting its clinical 
applicability. MRE11-NBS1-RAD50 exists in a 2:2:2 
complex [8] and it appears that RAD50 and NBS1 
transcription determines the amount of MRN complex 
formed, with MRE11 protein levels adapting in line with 
complex formation.
Regarding clinically-useful biomarkers, 
immunohistochemistry seems the most useful test and our 
results highlight the importance of studying MRE11 at the 
protein rather than mRNA level.
MATERIALS AND METHODS
Ethical approval was obtained from Leeds (East) 
Local Research Ethics Committee (studies 02/060 and 04/
Q1206/62).
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Tumour processing for IHC and RNA extraction
Eighty-eight tumour blocks from pre-radiotherapy 
transurethral resection of bladder tumour (TURBT) 
samples collected from 2002 to 2009 were identified as 
being suitable for this project. Patients were treated with 
radical radiotherapy for transitional cell carcinoma of the 
bladder at the Leeds Cancer Centre, West Yorkshire, UK, 
as per Choudhury et al [2]. An area of each formalin-fixed 
paraffin-embedded (FFPE) block was identified based 
on the matched haematoxylin-and-eosin (H+E) slide, 
where more than 70% of cells were tumour cells and 
the area appeared homogenous, to ensure that any core 
taken was representative of what was seen on the H+E 
slide. Four cores of tissue were taken from the identified 
area using a 0.6 mm tissue microarray corer (Beecher 
Instruments Inc). Total RNA was isolated using the HP 
RNA paraffin kit (Roche Diagnostics Ltd) according to 
manufacturer’s instructions, except that cores were lysed 
for 3 days, quantified by Nanodrop and 200 ng used in 
a 20 µl Taqman reverse transcription reaction (Applied 
Biosystems). Whole mount sections were stained for 
MRE11 and the area scored for percentage positive cells 
and intensity score as per Choudhury et al [2].
Cell culture
The bladder cancer cell lines RT112 and 253J were a 
generous gift from Professor MA Knowles, Leeds Institute 
of Molecular Medicine. They had been authenticated using 
by extensive genomic analysis (microsatellite typing, 
conventional karyotypic analysis, M-FISH and array based 
copy number analysis). The cell lines 5637, HT1376 and 
VMCUB-1 were purchased from the German Collection 
of Microorganisms and Cell Cultures (DSMZ), and J82, 
T24 and RT4 were purchased from the American Type 
Culture Collection. RT112, 253J, 5627 and T24 cells were 
culture in RPMI medium with 10% fetal calf serum (FCS, 
Invitrogen). HT1376 and VMCUB-1 cells in DMEM and 
10% FCS, J82 cells in MEM, 1% non-essential amino 
acids and 10% FCS and RT4 cells in McCoy’s 5A medium 
and 10% FCS. After resuscitation, cell lines were cultured 
for no more than three months.
Western blot
Cells were lysed with buffer containing 50 mM 
Hepes,100 mM NaCl,10 mM EDTA,1% w/v Triton, 4 mM 
sodium pyrophosphate, 2 mM Sodium orthovanadate, 10 
mM sodium fluoride, 50 mM β-glycerophosphate pH to 
7.5 with NaOH and 1% SDS then centrifuged at 14,000G 
for 10 minutes to obtain the total cell lysate. The BCA 
assay (Fisher) was used to determine protein concentration 
and 50 µg of protein was loaded on an 8% or 4-20% SDS-
PAGE gel, transferred to a nitrocellulose and probed 
with antibodies against MRE11 (Abcam, AB214), NBS1 
(Novus Biologicals), RAD50 (Cell Signalling, #3427), 
RAD51 (Santa Cruz), β-tubulin (Sigma) and β-actin 
(Abcam). Fluorescent secondary anti-mouse 800 and 
anti-rabbit 680 antibodies (Licor Biosciences) were used 
at 1:5,000 and visualised and quantified on an Odyssey 
machine. 
Real-time PCR 
For quantification of MRE11 mRNA in tumour 
cores and the bladder cancer cell line panel, 2 µl of 
reverse transcription product was used in a 20 µl QPCR 
using Hs00271551_m1 Taqman assay with Taqman 
gene expression master mix. ATP5B, Hs00969569_m1, 
and SDHA, Hs00188166_m1, were used as endogenous 
controls (Applied Biosystems) [28, 29]. RNA extracted 
from FFPE tissue is not of the same quality as RNA 
extracted from cell lines but valuable QPCR data can be 
obtained within the limitations involved and by monitoring 
endogenous control signal [30].
For expression analysis of mRNA in cell lines in 
subsequent experiments, SYBR green PCR master mix 
was used with primers for MRE11:F-TGAGGAGGTAC 
GTCGTTTCA,TCCATCTGGCATAAATGATGA, 
R-GTGGAAGTTTTCCTGCTCCA;RAD50:F-
GAGATTTCCCTCCTGGAACC,R-
ACATCACGAAATTGCAGACG;ATP5B:F-
ACCATCAAAGGATTCCAGCA,R-
GCTTTTGCCACAGCTTCTTC;SDHA:F-
TGGGAACAAGAGGGCATCTG,R-
CCACCACTGCATCAAATTCATG;C-
MYC:F-CAGCTGCTTAGACGCTGGATT,R-
GTAGAAATACGGCTGCACCGA.
RNA was isolated using the RNAeasy mini kit 
(Qiagen). Reverse transcription was performed using the 
High Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems). 
Luciferase assays
A vector containing MRE11-3’UTR cloned 
into the SGG_3UTR vector downstream of luc2P was 
purchased from Switchgear Genomics. Two hundred 
nanograms of plasmid vector was transfected into 5637 
cells seeded at 15,000 cells per well of a 96-well plate 
24 hours previously, along with 20 ng Renilla luciferase 
containing vector and pre-miR (miR-9 pm10022, miR-153 
PM10122 and pre-miRTM miRNA Precursor Molecules - 
negative control#1 AM17110, Applied Biosystems) to a 
final concentration of 250 nM using oligofectamine. Forty 
eight hours later firefly and renilla luciferase activity was 
detected on a Polstar Omega plate reader using dual-glo 
luciferase assay reagents (Promega).
Oncotarget1001www.impactjournals.com/oncotarget
MicroRNA expression
MicroRNA expression was determined by QPCR 
using Taqman Universal master mix (Applied Biosystems) 
and microRNA assays 00583 for miR-9, 001191 miR-
153, (Applied Biosystems). RNU44 (assay 1094) and 
RNU48 (assay 1006) were used as endogenous controls to 
normalise expression.
Polysome fractionation and analysis
Polysome fractionation and analysis was performed 
as previously described in Koritzinsky et al [31]. 
Briefly, 70% confluent cells were treated with 0.1 mg/
ml cycloheximide, lysed and the lysate applied to a 
sucrose gradient. After centrifugation, 1 ml fractions 
were collected that contained RNA bound to ribosomes 
with increasing weight and therefore increasing ribosome 
number. Fractions were pooled into groups containing 
0 or 1, 2 to 4, 5 to 7 and greater than 7 ribosomes, and 
RNA was isolated and reverse transcribed. The translation 
efficiency of specific genes was determined by QPCR 
analysis to detect the relative amount of each transcript 
in the pooled fraction groups. Average ribosome number 
per transcript was calculated and normalised against the 
average ribosome number for total RNA in each cell line, 
to adjust for differences in overall translation rate in each 
cell line.
Actinomycin D assay and cycloheximide 
treatment 
Cells (1.5 x106) were seeded in 10 cm plates the day 
before treatment with actinomycin D (Sigma) at 1 µg/ml 
and harvested 2, 4, 6, and 8 h later for RNA extraction 
as detailed above. Two hundred nanograms of RNA was 
used in a 20 ul reaction and 2 ul of a 1 in 5 dilution added 
to a 20 µl QPCR SYBR green reaction. A DMSO carrier 
control was harvested after 8 hours.
Cells (3 x106) were seeded in 15 cm plates the day 
before treatment with Cycloheximide at 100 µg/ml and 
harvested up to 36 h later for protein extraction, as detailed 
above. However, at 36 hours, cycloheximide caused cell 
death. A DMSO carrier control was plated at 1x106 cells to 
avoid over-confluency and harvested at 36 h.
Statistics
Spearman rank correlations and Student’s T test 
were carried out using SPSS 14.0 software. Unless 
otherwise stated, P values represent Student’s T test 
results.
ACKNOWLEDGEMENTS
We thank Ms Filomena Estevez for 
immunohistochemistry staining, and Ms Christiana 
Kartsonaki for her statistical help.
Financial support
RMM was funded by Cancer Research UK Project 
Grant C15140/A10441 and CR-UK Travel Grant C41641/
A13249.
MTWT was funded by Yorkshire Cancer Research 
Project Grant L350.
SJ was funded by a Medical Research Council 
studentship.
MK3 and BGW were funded from support from 
the Ontario Ministry of Health and Long Term Care 
(OMOHLTC), the Terry Fox Research Institute (New 
Frontiers Research Program (PPG09-020005 and New 
Investigator Award), the Ontario Institute for Cancer 
Research, and the Canadian Institute for Health Research 
(CIHR grant 201592). The views expressed do not 
necessarily reflect those of the OMOHLTC.
MK1 and AEK were funded by Cancer Research UK 
Programme Grant C5255/A15935.
Statement of author contributions
RMM and MK1 conceived and carried out 
experiments, analysed data, and generated figures. MTWT 
and SJJ carried out experiments and analysed data. MK3 
and GBW conceived experiments and analysed data. SB 
identified muscle-invasive tumour in paraffin blocks, and 
AEK conceived the study, made tumour cores and guided 
experiments. RMM, MK1, SJJ, MK3, BGW and AEK 
wrote the manuscript, and all authors had final approval of 
the submitted version.
REFERENCES
1. Kotwal S, Choudhury A, Johnston C, Paul AB, Whelan 
P and Kiltie AE. Similar treatment outcomes for radical 
cystectomy and radical radiotherapy in invasive bladder 
cancer treated at a United Kingdom specialist treatment 
center. International journal of radiation oncology, biology, 
physics. 2008; 70(2):456-463.
2. Choudhury A, Nelson LD, Teo MT, Chilka S, Bhattarai S, 
Johnston CF, Elliott F, Lowery J, Taylor CF, Churchman 
M, Bentley J, Knowles MA, Harnden P, Bristow RG, 
Bishop DT and Kiltie AE. MRE11 expression is predictive 
of cause-specific survival following radical radiotherapy 
for muscle-invasive bladder cancer. Cancer research. 2010; 
70(18):7017-7026.
3. Laurberg JR, Brems-Eskildsen AS, Nordentoft I, Fristrup 
Oncotarget1002www.impactjournals.com/oncotarget
N, Schepeler T, Ulhoi BP, Agerbaek M, Hartmann A, Bertz 
S, Wittlinger M, Fietkau R, Rodel C, Borre M, Jensen 
JB, Orntoft T and Dyrskjot L. Expression of TIP60 (tat-
interactive protein) and MRE11 (meiotic recombination 11 
homolog) predict treatment-specific outcome of localised 
invasive bladder cancer. BJU Int. 2012.
4. Angele S, Treilleux I, Bremond A, Taniere P and Hall J. 
Altered expression of DNA double-strand break detection 
and repair proteins in breast carcinomas. Histopathology. 
2003; 43(4):347-353.
5. Soderlund K, Stal O, Skoog L, Rutqvist LE, Nordenskjold 
B and Askmalm MS. Intact Mre11/Rad50/Nbs1 complex 
predicts good response to radiotherapy in early breast 
cancer. International journal of radiation oncology, biology, 
physics. 2007; 68(1):50-58.
6. Stewart GS, Maser RS, Stankovic T, Bressan DA, Kaplan 
MI, Jaspers NG, Raams A, Byrd PJ, Petrini JH and Taylor 
AM. The DNA double-strand break repair gene hMRE11 
is mutated in individuals with an ataxia-telangiectasia-like 
disorder. Cell. 1999; 99(6):577-587.
7. Takemura H, Rao VA, Sordet O, Furuta T, Miao ZH, Meng 
L, Zhang H and Pommier Y. Defective Mre11-dependent 
activation of Chk2 by ataxia telangiectasia mutated in 
colorectal carcinoma cells in response to replication-
dependent DNA double strand breaks. J Biol Chem. 2006; 
281(41):30814-30823.
8. Williams GJ, Lees-Miller SP and Tainer JA. Mre11-Rad50-
Nbs1 conformations and the control of sensing, signaling, 
and effector responses at DNA double-strand breaks. DNA 
Repair (Amst). 2010; 9(12):1299-1306.
9. Park YB, Chae J, Kim YC and Cho Y. Crystal structure 
of human Mre11: understanding tumorigenic mutations. 
Structure. 2011; 19(11):1591-1602.
10. Buis J, Stoneham T, Spehalski E and Ferguson DO. Mre11 
regulates CtIP-dependent double-strand break repair 
by interaction with CDK2. Nat Struct Mol Biol. 2012; 
19(2):246-252.
11. Zhuang J, Jiang G, Willers H and Xia F. Exonuclease 
function of human Mre11 promotes deletional 
nonhomologous end joining. The Journal of biological 
chemistry. 2009; 284(44):30565-30573.
12. Lamarche BJ, Orazio NI and Weitzman MD. The MRN 
complex in double-strand break repair and telomere 
maintenance. FEBS Lett. 2010; 584(17):3682-3695.
13. Garner KM, Pletnev AA and Eastman A. Corrected 
structure of mirin, a small-molecule inhibitor of the Mre11-
Rad50-Nbs1 complex. Nat Chem Biol. 2009; 5(3):129-130; 
author reply 130.
14. Dupre A, Boyer-Chatenet L, Sattler RM, Modi AP, Lee JH, 
Nicolette ML, Kopelovich L, Jasin M, Baer R, Paull TT 
and Gautier J. A forward chemical genetic screen reveals 
an inhibitor of the Mre11-Rad50-Nbs1 complex. Nat Chem 
Biol. 2008; 4(2):119-125.
15. Hui A, How C, Ito E and Liu FF. Micro-RNAs as diagnostic 
or prognostic markers in human epithelial malignancies. 
BMC Cancer. 2011; 11:500.
16. Schwanhausser B, Busse D, Li N, Dittmar G, Schuchhardt 
J, Wolf J, Chen W and Selbach M. Global quantification 
of mammalian gene expression control. Nature. 2011; 
473(7347):337-342.
17. de Sousa Abreu R, Penalva LO, Marcotte EM and Vogel C. 
Global signatures of protein and mRNA expression levels. 
Mol Biosyst. 2009; 5(12):1512-1526.
18. Maier T, Guell M and Serrano L. Correlation of mRNA and 
protein in complex biological samples. FEBS Lett. 2009; 
583(24):3966-3973.
19. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder 
D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey 
P, Varela I, Phillimore B, Begum S, McDonald NQ, Butler 
A, Jones D, et al. Intratumor heterogeneity and branched 
evolution revealed by multiregion sequencing. N Engl J 
Med. 2012; 366(10):883-892.
20. Garner KM and Eastman A. Variations in Mre11/Rad50/
Nbs1 status and DNA damage-induced S-phase arrest 
in the cell lines of the NCI60 panel. BMC Cancer. 2011; 
11:206:201-213.
21. Macfarlane LA and Murphy PR. MicroRNA: Biogenesis, 
Function and Role in Cancer. Current genomics. 2010; 
11(7):537-561.
22. Nelms BE, Maser RS, MacKay JF, Lagally MG and Petrini 
JH. In situ visualization of DNA double-strand break repair 
in human fibroblasts. Science. 1998; 280(5363):590-592.
23. Shen H, Morrison CD, Zhang J, Underwood W, 3rd, Yang 
N, Frangou C, Eng K, Head K, Bollag RJ, Kavuri SK, 
Rojiani AM, Li Y, Yan L, Hill A, Woloszynska-Read A, 
Wang J, et al. 6p22.3 amplification as a biomarker and 
potential therapeutic target of advanced stage bladder 
cancer. Oncotarget. 2013; 4(11):2124-2134.
24. Mongiat-Artus P, Miquel C, Van der Aa M, Buhard O, 
Hamelin R, Soliman H, Bangma C, Janin A, Teillac P, 
van der Kwast T and Praz F. Microsatellite instability 
and mutation analysis of candidate genes in urothelial 
cell carcinomas of upper urinary tract. Oncogene. 2006; 
25(14):2113-2118.
25. Wen Q, Scorah J, Phear G, Rodgers G, Rodgers S and 
Meuth M. A mutant allele of MRE11 found in mismatch 
repair-deficient tumor cells suppresses the cellular response 
to DNA replication fork stress in a dominant negative 
manner. Mol Biol Cell. 2008; 19(4):1693-1705.
26. Giannini G, Rinaldi C, Ristori E, Ambrosini MI, Cerignoli 
F, Viel A, Bidoli E, Berni S, D’Amati G, Scambia G, Frati 
L, Screpanti I and Gulino A. Mutations of an intronic repeat 
induce impaired MRE11 expression in primary human 
cancer with microsatellite instability. Oncogene. 2004; 
23(15):2640-2647.
27. Giannini G, Ristori E, Cerignoli F, Rinaldi C, Zani M, Viel 
A, Ottini L, Crescenzi M, Martinotti S, Bignami M, Frati 
L, Screpanti I and Gulino A. Human MRE11 is inactivated 
Oncotarget1003www.impactjournals.com/oncotarget
in mismatch repair-deficient cancers. EMBO Rep. 2002; 
3(3):248-254.
28. Ohl F, Jung M, Radonic A, Sachs M, Loening SA and Jung 
K. Identification and validation of suitable endogenous 
reference genes for gene expression studies of human 
bladder cancer. J Urol. 2006; 175(5):1915-1920.
29. Andersen CL, Jensen JL and Orntoft TF. Normalization 
of real-time quantitative reverse transcription-PCR data: 
a model-based variance estimation approach to identify 
genes suited for normalization, applied to bladder and colon 
cancer data sets. Cancer Res. 2004; 64(15):5245-5250.
30. Conway C, Mitra A, Jewell R, Randerson-Moor J, Lobo S, 
Nsengimana J, Edward S, Sanders DS, Cook M, Powell B, 
Boon A, Elliott F, de Kort F, Knowles MA, Bishop DT and 
Newton-Bishop J. Gene expression profiling of paraffin-
embedded primary melanoma using the DASL assay 
identifies increased osteopontin expression as predictive 
of reduced relapse-free survival. Clin Cancer Res. 2009; 
15(22):6939-6946.
31. Koritzinsky M, Seigneuric R, Magagnin MG, van den 
Beucken T, Lambin P and Wouters BG. The hypoxic 
proteome is influenced by gene-specific changes in mRNA 
translation. Radiother Oncol. 2005; 76(2):177-186.
